Dr Danjou is a Clinical Pharmacologist from Paris University. He trained at the Pitié-Salpétriêre Hospital and received his Medical Degree in 1984 which he followed with a PhD in human biology in 1990. After doing Post-Doctoral studies in anxiety at the New York Psychiatric Institute, and a short university career in France, he spent 20 years in the Pharmaceutical Industry where he was involved in the early development of compounds that were successfully registered such as Zolpidem (Synthelabo), Zaleplon and Venlafaxine (Wyeth).

As Head of Clinical Pharmacology at Sanofi, Dr Danjou gained experience in Clinical Psychiatry and Human Pharmacodynamics. He also held a translational medicine role with Merck Sharp & Dohme at Terlings Park. In 2011 he joined the French CNS specialized CRO, Forenap, as Chief Scientific Officer. In addition to Bionomics, he is member of the scientific advisory boards of Enkam Pharmaceuticals A/S in Denmark and  Manros Therapeutics in France. Dr Danjou has initiated the International Pre-competitive Pharmaco-EEG Consortium (IPPEC) on the use of EEG as a translational biomarker and as coordinator, has submitted a EU FR7 large frame project on schizophrenia (Stigma®). In parallel Dr Danjou has recently completed two years of training and working on Pain Disorders at a Paris Hospital.